华健康和BeOne药品同意达成价值高达19亿美元的全球协议,用于癌症免疫疗法HH160. Huahui Health and BeOne Medicines agree to global deal worth up to $1.9 billion for cancer immunotherapy HH160.

中国生物技术公司华健康和全球性瘤学公司BeOne药物已同意为HH160进行全球交易,该药是一种癌症免疫疗法. Chinese biotech Huahui Health and global oncology company BeOne Medicines have agreed to a global deal for HH160, a cancer immunotherapy. 为了开发和销售该药物, BeOne将提前支付2000万美元以及高达19亿美元的里程碑费用. 该药物针对三种与癌症相关的蛋白质. BeOne will pay $20 million upfront and up to $1.9 billion in milestones to develop and sell the drug, which targets three cancer-related proteins.